Insider's Analysis from Wilson Sonsini: Advantages Of China's Biogeneric Regulatory Pathway (Part 2 Of 2)
This article was originally published in PharmAsia News
Executive Summary
By Jeff Guise and Ben Carson, Wilson Sonsini Goodrich & Rosati, San Dieg